Patients with negative troponin or elevated C-reactive protein had a higher mortality rate after treatment with abciximab for 48 hours than with placebo : 8.5 % versus 5.8 % in those with negative troponin ( P = 0.02 ) , 16.3 % versus 12.1 % in those with elevated C-reactive protein ( P = 0.04 ) .
